K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Tourmaline Bio (TRML – Research Report) today. The company’s shares ...

Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for starting doses.